Drug Approval | September 30, 2022
USFDA inspects Zydus Lifesciences Ahmedabad SEZ facility
The company will address the observations within a stipulated timeline working with the regulators
The company will address the observations within a stipulated timeline working with the regulators
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
He is a seasoned professional having worked in reputed corporates in API business with over 35+ years of experience covering manufacturing, general management, and business
Funds raised will be used to develop technology and foster healthcare partnerships
Transformation to pure-play Innovative Medicines company nears completion
The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
One in two women with advanced ovarian cancer has an HRD-positive tumor
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Subscribe To Our Newsletter & Stay Updated
